Morgan Joseph downgrades BioMarin Pharmaceutical (Nasdaq: BMRN) from Buy to Hold.

Morgan analyst says, "Although fundamentals remain strong at BioMarin ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE